TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05920122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine gluconate with 70% alcohol
Description: Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Chlorhexidine Gluconate aqueous solution
Description: Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
Study: NCT04736056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills
Description: Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
Study: NCT05806554

Intervention type: DEVICE
Intervention: Continuous glucose monitoring device
Description: Continuous glucose monitoring device

Intervention type: DEVICE
Intervention: Continuous glucose monitoring device
Description: Continuous glucose monitoring device
Study: NCT05510687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glasses to correct presbyopia
Description: Participants will receive eyeglasses to correct presbyopia, as per the power determined in the eye examination.
Study: NCT05295225

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Green Light Emitting Diode
Description: GLED exposure for two hours

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: White Light Emitting Diode
Description: WLED exposure for two hours
Study: NCT06128551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Assigned interventions
Description: Drug: RMC-6291 and RMC-6236 Oral tablets
Study: NCT03919916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus plane block
Description: Placement of initial local anaesthetic bolus and catheter for continuous infusion in the plane between latissimus dorsi and serratus anterior in the midaxillary line at the level of the 5th rib

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: Computerised pump device facilitating the patient self administration and titration as needed of morphine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia
Description: Computerised pump device facilitating the patient self administration and titration as needed of morphine
Study: NCT04099342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEAST RP
Description: FEAST with standard electrode configuration and reversed current flow

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEAST RP
Description: FEAST with standard electrode configuration and reversed current flow
Study: NCT05713227

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White rice
Description: 185 g Jasmine (white) rice boiled in 356 g water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gellan gum
Description: Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
Study: NCT06094894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sucralose
Description: Food additive used to replace sugar providing a sweet taste without calories.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Cornstarch without significant physiological effects
Study: NCT04711317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high flow oxygen
Description: Pregnant women scheduled for cesarian section in general anaesthesia will be preoxygenated using nasal high flow oxygen
Study: NCT06690567

Intervention type: DEVICE
Intervention: Impella implantation
Description: To implante Impella
Study: NCT06690671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib in combination with anti-PD-1
Description: Golidocitinib 150/75 mg once daily (QD) with anti-PD-1 （200 mg IV Q3W），21 days in one cycle.
Study: NCT06257420

Intervention type: DRUG
Intervention: Rapamycin
Description: Once weekly oral rapamycin

Intervention type: DRUG
Intervention: Rapamycin
Description: Once weekly oral rapamycin
Study: NCT05696522

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: Stereotactic ablative radiotherapy will be delivered to a volume of ventricular myocardium responsible for the clinical ventricular tachycardia.
Study: NCT04586660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XGEVA®
Description: Participants will receive XGEVA® 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15.
Study: NCT05705791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuiremSpheres
Description: 166Holmium selective internal intra-arterial radiation therapy at C1D15 of the Atezolizumab and Bevacizumab therapy
Study: NCT05777694

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle
Description: the investigators performed spinal anesthesia with 25 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle
Description: the investigators performed spinal anesthesia with 25 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle
Description: the investigators performed spinal anesthesia with 25 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle
Description: the investigators performed spinal anesthesia with 26 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle
Description: the investigators performed spinal anesthesia with 26 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle
Description: the investigators performed spinal anesthesia with 26 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle
Description: the investigators performed spinal anesthesia with 27 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle
Description: the investigators performed spinal anesthesia with 27 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle
Description: the investigators performed spinal anesthesia with 27 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
Study: NCT05894655

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 walk-up, on-site testing strategy
Description: This strategy is a no-appointment, walk-up point-of-care PCR and rapid testing strategy for clinic patients and community members. It will be offered 5 days/week for 7 hours during the first 3 months of the trial at Clinic 1. The intensity will decrease over the trial ending with 1 SYH Medical Assistant overseeing the testing protocol. Bilingual research staff will be trained to oversee onsite testing.
Study: NCT05347394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-708
Description: Solution or suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-708
Description: Solution or suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-708 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-708 for oral administration.
Study: NCT05324137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection
Study: NCT06030427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Participate in weight management program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive patient education handouts
Study: NCT05324137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05727462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy with TECAR
Description: The following myofascial release techniques will be applied:~Myofascial release of the upper trapezius Gross stretch, vertical gross stretch, and focused stretch of the upper trapezius Myofascial release at the cranial base Gross release of the sternocleidomastoid muscle~Additionally, the following ischemic compression technique will be applied:~Ischemic compression on the upper trapezius muscle Manual therapy manipulations will be administered in combination with a capacitive conventional electrode and two special electrode bracelets that turn the therapist's hands into anti-static electrodes. High-frequency currents will be applied at frequencies of 300 kHz, 500 kHz, and 1 MHz, with a flexible self-adhesive grounding electrode placed on the thoracic spine for reference.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy without TECAR
Description: Participants in this group will follow the same manual protocol as the first group, without the application of high-frequency current. Each manual therapy session will begin with a ten-minute preparation involving light massage and stretching. The massage will include the effleurage technique, followed by petrissage and kneading, focusing on the cervical and thoracic areas, particularly the upper trapezius, suboccipital region, and cervical paraspinal muscles. Stretching will be applied to the upper trapezius, levator scapulae, and sternocleidomastoid muscles.
Study: NCT04416633

Intervention type: DRUG
Group type: OTHER
Intervention: Durvalumab
Description: 500-mg/120-mg IV
Study: NCT06565208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAT-3247
Description: SAT-3247 is an oral tablet that is a potent, muscle penetrant, small molecule inhibitor of AAK1; inhibition of AAK1 rescues perturbed asymmetric division of satellite stem cells, resulting in increased muscle regeneration in animal models of DMD. In vitro and in vivo animal pharmacology studies have demonstrated the efficacy of SAT-3247 in improving muscle strength and the necessary target coverage to maximize functional muscle improvement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: matched placebo
Study: NCT06131398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 355
Description: Short-term intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 355
Description: Short-term intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Short-term IV infusion
Study: NCT04334759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab and Nivolumab
Description: Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years
Study: NCT06464471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-reported online geriatric assessment (CHAMP)
Description: The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
Study: NCT06048536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-130A-01 Transdermal patch
Description: MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-130A-01 Transdermal patch
Description: MR-130A-01 transdermal patch, containing 3.64 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-130A-01 Transdermal patch
Description: MR-130A-01 transdermal patch, containing 3.64 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-130A-01 Transdermal patch
Description: MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 28 days per cycle with no patch free period
Study: NCT05766787

Intervention type: DEVICE
Group type: OTHER
Intervention: Serafilcon A contact lenses
Description: Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
Study: NCT06048536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-130A-01 Transdermal patch
Description: MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 28 days per cycle with no patch free period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-130A-01 Transdermal patch
Description: MR-130A-01 Transdermal patch MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 21 days with a 7-day patch free period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-130A-01 Transdermal patch
Description: MR-130A-01 Transdermal patch MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 21 days with a 7-day patch free period.
Study: NCT06030427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: View behavioral educational PowerPoint presentation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Complete virtual behavioral weight management with an integrated mindfulness component program
Study: NCT05766787

Intervention type: DEVICE
Group type: OTHER
Intervention: Serafilcon A contact lenses
Description: Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
Study: NCT05853120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.
Study: NCT04904575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector spinae plane block
Description: Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%.
Study: NCT05377203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadruple combination of half doses therapy→Dual combination of standard dose therapy
Description: Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.~Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual combination of standard dose therapy→ Quadruple combination of half doses therapy
Description: Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.~Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.
Study: NCT06030427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear Fitbit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Relaxation
Description: Complete mindfulness components

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies
Study: NCT05766787

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
Study: NCT06030427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05278988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRS Regimen V
Description: PRS Regimen V(bedaquiline, delamanid, clofazimine, pyrazinamide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDR-TB Treatment Regimen(WHO)
Description: Treatment according to WHO MDR-TB treatment guidelines (2019)
Study: NCT06401005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab (AK104)
Description: 8Gy\*3 SBRT to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK104 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of doxorubicin 50mg/m2 (Q3W) + cyclophosphamide 600mg/m2 (Q3W) were administered, followed by four cycles of sequential albumin paclitaxel (125 mg/m2, d1, d8) and carboplatin (AUC=6, d1, Q3W) for 4 cycles. Postoperative completion of 9 cycles of immunotherapy was continued ± the need for postoperative adjuvant radiotherapy was confirmed based on the patient's preoperative status.